Literature DB >> 16332481

Barrett's epithelium after antireflux surgery.

Giovanni Zaninotto1, Mauro Cassaro, Gianmaria Pennelli, Giorgio Battaglia, Fabio Farinati, Martina Ceolin, Mario Costantini, Alberto Ruol, Emanuela Guirroli, Christian Rizzetto, Giuseppe Portale, Ermanno Ancona, Massimo Rugge.   

Abstract

Barrett's epithelium (BE), defined as endoscopically visible, histologically proved intestinal-type epithelium in the esophagus, is considered the ultimate consequence of long-standing gastro(duodeno)esophageal reflux disease (GERD). Recent reports suggest that effective antireflux therapy may promote the regression of this metaplastic process. This study aimed to establish whether antireflux surgery (laparoscopic fundoplication) can induce any endoscopic and/or histologic changes in BE. Thirty-five consecutive cases of BE (11 short-segment [SBE] and 24 long-segment [LBE]) were considered. All patients underwent extensive biopsy sampling before and after surgery (mean follow-up, 28 months; range, 12-99 mo). In all cases, (a) intestinal metaplasia (IM) extension (H&E), (b) IM phenotype (high-iron diamine [HID]), and (c) Cdx2 immunohistochemical expression were histologically scored in the biopsy material obtained before and after fundoplication. After surgery, a significant decrease in IM extension and a shift from incomplete- to complete-type IM were documented in SBE. No significant changes occurred in the LBE group in terms of IM extension or histochemical phenotype. A drop in the immunohistochemical expression of Cdx2 protein was also only documented in the SBE group. Antireflux surgery significantly modifies the histologic phenotype of SBE, but not of LBE.

Entities:  

Mesh:

Year:  2005        PMID: 16332481     DOI: 10.1016/j.gassur.2005.09.027

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.267


  19 in total

1.  Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features.

Authors:  Richard R Gurski; Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester; Cedric G Bremner; Parakrama T Chandrasoma; Tom R DeMeester
Journal:  J Am Coll Surg       Date:  2003-05       Impact factor: 6.113

2.  Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results.

Authors:  R E Sampliner; B Fennerty; H S Garewal
Journal:  Gastrointest Endosc       Date:  1996-11       Impact factor: 9.427

3.  Standards for oesophageal manometry. A position statement from the Gruppo Italiano di Studio Motilità Apparato Digerente (GISMAD).

Authors:  S Passaretti; G Zaninotto; N Di Martino; P Leo; M Costantini; F Baldi
Journal:  Dig Liver Dis       Date:  2000 Jan-Feb       Impact factor: 4.088

Review 4.  Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy.

Authors:  S R DeMeester; T R DeMeester
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

5.  Long-term outcome of antireflux surgery in patients with Barrett's esophagus.

Authors:  W L Hofstetter; J H Peters; T R DeMeester; J A Hagen; S R DeMeester; P F Crookes; P Tsai; F Banki; C G Bremner
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

6.  Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.

Authors:  A J Cameron; H A Carpenter
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

7.  Clinical and histologic follow-up after antireflux surgery for Barrett's esophagus.

Authors:  Steven P Bowers; Samer G Mattar; C Daniel Smith; J Patrick Waring; John G Hunter
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

8.  Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis.

Authors:  Kathleen E Corey; Sarah M Schmitz; Nicholas J Shaheen
Journal:  Am J Gastroenterol       Date:  2003-11       Impact factor: 10.864

9.  Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility.

Authors:  J R Jamieson; H J Stein; T R DeMeester; L Bonavina; W Schwizer; R A Hinder; M Albertucci
Journal:  Am J Gastroenterol       Date:  1992-09       Impact factor: 10.864

10.  Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia.

Authors:  Gabriel M Groisman; Mary Amar; Alona Meir
Journal:  Mod Pathol       Date:  2004-10       Impact factor: 7.842

View more
  9 in total

1.  Regression of low-grade noninvasive neoplasia in barrett's epithelium: should we lower our guard?

Authors:  Giovanni Zaninotto; Massimo Rugge
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

2.  Laparoscopic treatment of obese patients with gastroesophageal reflux disease and Barrett's esophagus: a prospective study.

Authors:  Italo Braghetto; Owen Korn; Attila Csendes; Luis Gutiérrez; Héctor Valladares; Max Chacon
Journal:  Obes Surg       Date:  2012-05       Impact factor: 4.129

3.  EAES recommendations for the management of gastroesophageal reflux disease.

Authors:  Karl Hermann Fuchs; Benjamin Babic; Wolfram Breithaupt; Bernard Dallemagne; Abe Fingerhut; Edgar Furnee; Frank Granderath; Peter Horvath; Peter Kardos; Rudolph Pointner; Edoardo Savarino; Maud Van Herwaarden-Lindeboom; Giovanni Zaninotto
Journal:  Surg Endosc       Date:  2014-05-02       Impact factor: 4.584

4.  Long-term follow-up of Barrett's epithelium: medical versus antireflux surgical therapy.

Authors:  Giovanni Zaninotto; Paola Parente; Renato Salvador; Fabio Farinati; Chiara Tieppo; Nicola Passuello; Lisa Zanatta; Matteo Fassan; Francesco Cavallin; Mario Costantini; Claudia Mescoli; Giorgio Battaglia; Alberto Ruol; Ermanno Ancona; Massimo Rugge
Journal:  J Gastrointest Surg       Date:  2011-11-16       Impact factor: 3.452

Review 5.  Effect of medical and surgical treatment of Barrett's metaplasia.

Authors:  Eelco B Wassenaar; Brant K Oelschlager
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

6.  Surgical treatments for esophageal cancers.

Authors:  William H Allum; Luigi Bonavina; Stephen D Cassivi; Miguel A Cuesta; Zhao Ming Dong; Valter Nilton Felix; Edgar Figueredo; Piers A C Gatenby; Leonie Haverkamp; Maksat A Ibraev; Mark J Krasna; René Lambert; Rupert Langer; Michael P N Lewis; Katie S Nason; Kevin Parry; Shaun R Preston; Jelle P Ruurda; Lara W Schaheen; Roger P Tatum; Igor N Turkin; Sylvia van der Horst; Donald L van der Peet; Peter C van der Sluis; Richard van Hillegersberg; Justin C R Wormald; Peter C Wu; Barbara M Zonderhuis
Journal:  Ann N Y Acad Sci       Date:  2014-09       Impact factor: 5.691

Review 7.  Antireflux surgery for dysplastic Barrett.

Authors:  Marco E Allaix; Marco G Patti
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

8.  The patterns of reflux can affect regression of non-dysplastic and low-grade dysplastic Barrett's esophagus after medical and surgical treatment: a prospective case-control study.

Authors:  Salvatore Tolone; Paolo Limongelli; Marco Romano; Alessandro Federico; Giovanni Docimo; Roberto Ruggiero; Luigi Brusciano; Gianmattia Del Genio; Ludovico Docimo
Journal:  Surg Endosc       Date:  2014-07-17       Impact factor: 4.584

9.  Long-term results (6-10 years) of laparoscopic fundoplication.

Authors:  Giovanni Zaninotto; Giuseppe Portale; Mario Costantini; Christian Rizzetto; Emanuela Guirroli; Martina Ceolin; Renato Salvador; Sabrina Rampado; Oberdan Prandin; Alberto Ruol; Ermanno Ancona
Journal:  J Gastrointest Surg       Date:  2007-07-10       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.